Table 2.
Major clinical outcomes of study population during the follow-up period according to baseline liver steatosis status.
|
Liver steatosis (n = 241) |
No liver steatosis (n = 283) |
p value | |
|---|---|---|---|
| Length of follow up (months) (range) | 72.4 (0.96–168.48) | 80.2 (1.44–168) | 0.085 |
| Composite outcome of all-cause mortality and cancer, % (n) | 15.4 (37) | 4.6 (13) | < 0.001 |
| All-cause mortality, % (n) | 6.6 (16) | 1.4 (4) | 0.010 |
| Malignancy (all types), % (n) | 13.7 (33) | 3.2 (9) | < 0.001 |
| Hepatocellular carcinoma, % (n) | 5.8 (14) | 1.4 (4) | 0.010 |
| Extra-hepatic malignancies, % (n) | 9.9 (19) | 1.8 (5) | 0.010 |
| Initiation of anti-HBV treatment, % (n) | 29.5 (71) | 48.8 (138) | < 0.001 |